Eastwood Bio-Medical Canada Inc

As of April 30, 2026, Eastwood Bio-Medical Canada Inc has 68.89M shares outstanding.

As of April 30, 2026, Eastwood Bio-Medical Canada Inc maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -136.74, reflecting losses generated across the asset base.

As of the close on October 20, 2026, Eastwood Bio-Medical Canada Inc's stock has gained approximately 323.81% over the past 52 weeks. The 50-day moving average sits at 1.29, while the 200-day moving average is 2.64.

Over the twelve months ended April 30, 2026, Eastwood Bio-Medical Canada Inc generated 739,106.00 in revenue and converted that into -320,873.00 in net income, yielding earnings per share of 0.00. EBITDA reached -276,025.00, while operating income came in at -296,932.00.

As of April 30, 2026, Eastwood Bio-Medical Canada Inc holds 9,038.00 in cash and equivalents against 67,982.00 in total debt, resulting in a net debt position of 58,944.00. Total book value stands at -1.72M, with working capital of -1.88M providing operational flexibility.

Eastwood Bio-Medical Canada Inc produced 4,677.00 in operating cash flow over the twelve months ended April 30, 2026.

Over the twelve months ended April 30, 2026, Eastwood Bio-Medical Canada Inc posted a gross margin of 71.04, reflecting its pricing power and cost economics. The operating margin of -40.17 and net profit margin of -43.41 provide insight into operational efficiency.